The U.S. Supreme Court is reviewing a case on the access to the abortion pill mifepristone, which could influence medication abortion availability.

The case questions if the FDA neglected safety concerns when easing restrictions on mifepristone, such as permitting mail-order distribution.

Medical experts defend mifepristone's safety, with serious complications under 0.32% and effectiveness at 97.4%, while opponents cite safety issues.

Changes to mifepristone access could have broader political consequences, affecting the presidential race and future legislative actions on abortion rights.

The court's decision may lead to a cascade of state challenges, potentially rehashing the same legal battles over reproductive rights in the future.

Abortion-rights activists and healthcare providers are exploring alternatives, like misoprostol-only abortions, to ensure continued access despite potential restrictions.